Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JAIMIESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JAIMIESS.
GENCEPT 10/11-21 vs JAIMIESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Category C
Category C
Oral Contraceptive
Oral Contraceptive, Combined